Gender differences in chronic kidney disease: Underpinnings and therapeutic implications

Kidney and Blood Pressure Research

Volumn 33, Issue 5, 2010, Pages 383-392

  Carrero, Juan Jesús ^a  

^a Centre for Gender Medicine   (Sweden)

Author keywords

Compliance; Estrogen; Testosterone

Indexed keywords

ATTITUDE TO ILLNESS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; HYPOPHYSIS GONAD SYSTEM; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT RESPONSE;

CHRONIC DISEASE; DISEASE MANAGEMENT; FEMALE; HUMANS; KIDNEY DISEASES; MALE; SEX DISTRIBUTION; SEX FACTORS;

EID: 77957803570     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320389     Document Type: Review

References (121)

1. Vitale C, Mendelsohn ME, Rosano GM: Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009; 6: 532-542.
2. Lawlor DA, Ebrahim S, Davey Smith G: Sex matters: secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 2001; 323:541-545.
3. King BM: Opinion: a call for proper usage of 'gender' and 'sex' in biomedical publications. Am J Physiol Regul Integr Comp Physiol 2010; 298:R1700-R1701.
4. Silbiger S, Neugarten J: Gender and human chronic renal disease. Gend Med 2008; 5(suppl A):S3-S10.
5. Neugarten J, Acharya A, Silbiger SR: Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11:319-329.
6. Evans M, Fryzek JP, Elinder CG, Cohen SS, McLaughlin JK, Nyren O, Fored CM: The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis 2005; 46:863-870.
7. Eriksen BO, Ingebretsen OC: The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. K idney Int 2006; 69: 375-382.
8. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Differences between women and men with chronic renal disease. Nephrol Dia l Transplant 1998; 13: 1430-1437.
9. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS: The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 2003; 18: 2047-2053.
10. Halbesma N, Brantsma AH, Bakker SJ, Jan-sen DF, Stolk RP, De Zeeuw D, De Jong PE, Gansevoort RT: Gender differences in predictors of the decline of renal function in the general population. Kidney Int 2008; 74: 505-512.
11. Verhave JC, Hillege HL, Burgerhof JG, Navis G, de Zeeuw D, de Jong PE: Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J A m Soc Nephrol 2003; 14: 1330-1335.
12. Kollerits B, Fliser D, Heid IM, Ritz E, Kro-nenberg F: Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the mild to moderate Kidney disease study. Kidney Int 2007; 71: 1279-1286. (Pubitemid 46884246)
13. Carrero JJ, Cordeiro AC, Lindholm B, Sten-vinkel P: The emerging pleiotrophic role of adipokines in the uremic phenotype: current opinion in nephrology and hypertension 2010; 19: 37-42.
14. Ahmed SB, Fisher ND, Hollenberg NK: Gender and the renal nitric oxide synthase system in healthy humans. Clin J Am Soc Nephrol 2007; 2:926-931.
15. Sandberg K: Mechanisms underlying sex differences in progressive renal disease. Gend Med 2008; 5:10-23.
16. Stringer KD, Komers R, Osman SA, Oyama TT, Lindsley JN, Anderson S: Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int 2005; 68:1729-1739.
17. Elliot SJ, Berho M, Korach K, Doublier S, Lupia E, Striker GE, Karl M: Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient c57bl/6j mice develop glomerulosclerosis. Kidney Int 2007; 72:464-472.
18. Maric C, Sandberg K, Hinojosa-Laborde C: Glomerulosclerosis and tubulointerstitial fi-brosis are attenuated with 17beta-estradiol in the aging dahl salt sensitive rat. J Am Soc Nephrol 2004; 15:1546-1556.
19. Catanuto P, Doublier S, Lupia E, Fornoni A, Berho M, Karl M, Striker GE, Xia X, Elliot S: 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of t ype 2 diabetes. Kidney Int 2009; 75: 1194-1201.
20. Metcalfe PD, Leslie JA, Campbell MT, Mel-drum DR, Hile KL, Meldrum KK: Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am J Physiol 2008; 294:E435-E443.
21. Lu H, Lei X, Klaassen C: Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats. Kidney Int 2006; 70: 1920-1928.
22. Verzola D, Villaggio B, Procopio V, Gandolfo MT, Gianiorio F, Fama A, Tosetti F, Traverso P, Deferrari G, Garibotto G: Androgen-me-diated apoptosis of kidney tubule cells: role of c-jun amino terminal kinase. Biochem Biophys Res Commun 2009; 387: 531-536.
23. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM, Lansang MC, Steva-novic R, Fisher ND, Hollenberg NK: Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28: 1988-1994.
24. Agarwal M, Selvan V, Freedman BI, Liu Y, Wagenknecht LE: The relationship between albuminuria and hormone therapy in post-menopausal women. Am J Kidney Dis 2005; 45:1019-1025.
25. Szekacs B, Vajo Z, Varbiro S, Kakucs R, Vas-laki L, Acs N, Mucsi I, Brinton EA: Post-menopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG 2000; 107:1017-1021.
26. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT: Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 16 1: 2000-2005.
27. Ahmed SB, Culleton BF, Tonelli M, Klaren-bach SW, Macrae JM, Zhang J, Hemmelgarn BR: Oral estrogen therapy in postmeno-pausal women is associated with loss of kidney function. Kidney Int 2008; 74: 370-376.
28. Silbiger S: The effects of hormone replacement therapy on renal function. Nat Clin Pract 2009; 5: 6-7.
29. Stehman-Breen CO, Gillen D, Gipson D: Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney Int 1999; 56: 2243-2247.
30. Kallner A, Khatami Z: How does the MDRD study equation compare with serum creatinine in routine healthcare? Anatomy of MDRD-EGFR. Scand J Clin Lab Invest Suppl 2008; 241: 39-45.
31. Zoccali C, Kramer A, Jager KJ: Chronic kidney disease and end-stage renal disease: a review produced to contribute to the report 'The Status of Health in the European Union: Towards a Healthier Europe'. Nephrol Dial Transplant Plus 2009, in press.
32. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276.
33. Wingard DL, Suarez L, Barrett-Connor E: The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol 1983; 117: 165-172.
34. Kardys I, Vliegenthart R, Oudkerk M, Hof-man A, Witteman JC: The female advantage in cardiovascular disease: do vascular beds contribute equally? Am J Epidemiol 2007; 166:403-412.
35. Isles CG, Hole DJ, Hawthorne VM, Lever AF: Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley Survey: comparison with men. Lancet 1992; 339:702-706.
36. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK: Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. BMJ 1997; 315:722-729.
37. Stel VS, Tomson C, Ansell D, Casino FG, Collart F, Finne P, Ioannidis GA, De Meester J, Salomone M, Traynor JP, Zurriaga O, Jager KJ: Level of renal function in patients starting dialysis: an ERA-EDTA registry study. Nephrol Dial Transplant 2010, E-pub ahead of print.
38. Obrador GT, Arora P, Kausz AT, Ruthazer R, Pereira BJ, Levey AS: Level of renal function at the initiation of dialysis in the US: end-stage renal disease population. Kidney Int 1999; 56: 2227-2235.
39. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG: Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002; 13: 2125-2132.
40. Villar E, Remontet L, Labeeuw M, Ecochard R: Effect of age, gender, and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol 20 07; 18: 2125-2134.
41. Villar E, Chang SH, McDonald SP: Incidences, treatments, outcomes, and sex effect on survival in patients with endstage renaldisease by diabetes status in Australia and New Zealand (1991-2005). Diabetes Care 2007; 30:3070-3076.
42. Carrero JJ, de Mutsert R, Axelsson J, Dekkers OM, Jager KJ, Boeschoten EW, Krediet RT, Dekker FW: Sex differences in the impact of diabetes on mortality in chronic dialysis patients. Nephrol Dial Transplant 2010, E-pub ahead of print.
43. Oien CM, Reisaeter AV, Os I, Jardine A, Fell-strom B, Holdaas H: Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the alert study. Clin Transplant 2006; 20: 374-382.
44. Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new he-modialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010; 5:805-813.
45. Schlieper G, Brandenburg V, Djuric Z, Dam-janovic T, Markovic N, Schurgers L, Kruger T, Westenfeld R, Ackermann D, Haselhuhn A, Dimkovic S, Ketteler M, Floege J, Dim-kovic N: Risk factors for cardiovascular calcifications in non-diabetic caucasian hae-modialysis patients. Kidney Blood Press Res 2009; 32:161-168.
46. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, Couttenye MM, De Broe ME, D'Haese PC: Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Tra nsplant 2003; 18: 1159-1166.
47. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F: Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001; 12:1242-1248.
48. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, Walston J, Kimura M, Aviv A: Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 2007; 165:14-21.
49. Carrero JJ, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimburger O, Barany P, Radhakrishnan K, Lindholm B, Soveri I, Nordfors L, Shiels PG: Telomere attrition is associated with inflammation, low fetuin-a levels and high mortality in prevalent hae-modia lysis patients. J Intern Med 2008; 263: 302-312.
50. Carrero JJ, Stenvinkel P: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009; 4(suppl 1): S49-S55.
51. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC: Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 20 08; 19: 2204-2210.
52. Hu xley R, Barzi F, Woodwa rd M: E xcess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332:73-78.
53. Barrett-Connor E, Wingard DL: Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 1983; 11 8: 489-496.
54. Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL: Sex differences in fasting glycemia as a risk factor for ische-mic heart disease death. Am J Epidemiol 1991; 133: 565-576.
55. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 2008; 26: 291-299.
56. Stenvinkel P, Wanner C, Metzger T, Heim-burger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798.
57. Stenvinkel P, Barany P, Chung SH, Lindholm B, Heimburger O: A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrol Dial Transplant 2002; 17: 1266-1274.
58. Carrero JJ, Chmielewski M, Axelsson J, Snaedal S, Heimburger O, Barany P, Suliman ME, Lindholm B, Stenvinkel P, Qureshi AR: Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr 2008; 27:557-564.
59. Maruyama Y, Nordfors L, Stenvinkel P, Heimburger O, Barany P, Pecoits-Filho R, Axelsson J, Hoff CM, Holmes CJ, Schalling M, Lindholm B: Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. Blood Purif 2005; 23: 384-393.
60. Carrero JJ, Aguilera A, Stenvinkel P, Gil F, Selgas R, Lindholm B: Appetite disorders in uremia. J Ren Nutr 2008; 18: 107-113.
61. Carrero JJ: Identification of patients with eating disorders: clinical and biochemical signs of appetite loss in dialysis patients. J Ren Nutr 2009; 19: 10-15.
62. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, Lindholm B, Stenvinkel P: Comparison of nutritional and inf lammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 20 07; 85: 695-701.
63. Geary N: Sex differences in disease anorexia. Nutrition 2001; 17: 499-507.
64. Lyons PM, Truswell AS, Mira M, Vizzard J, Abraham SF: Reduction of food intake in the ovulatory phase of the menstrual cycle. Am J Clin Nutr 1989; 49:1164-1168.
65. Li ET, Tsang LB, Lui SS: Menstrual cycle and voluntary food intake in young Chinese women. Appetite 1999; 33:109-118.
66. Barr SI, Janelle KC, Prior JC: Energy intakes are higher during the luteal phase of ovula-tory menstrual cycles. Am J Clin Nutr 1995; 61:39-43.
67. Intebi AD, Garau L, Brusco I, Pagano M, Gaillard RC, Spinedi E: Alzheimer's disease patients display gender dimorphism in circulating anorectic adipokines. Neuroimmunomodulation 2002; 10: 351-358.
68. Walsh D, Donnelly S, Rybicki L: The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000; 8:175-179.
69. Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR, Barany P, Heim-burger O, Suliman ME, Alvestrand A, Lind-holm B, Stenvinkel P: Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007; 262: 690-701.
70. Weisinger JR, Bellorin-Font E: Outcomes associated with hypogonadism in women with chronic kidney disease. Adv Chron Kidney Dis 2004; 11:361-370.
71. Kramer HM, Curhan G, Singh A: Hemodi-alysis and estrogen levels in postmenopausal (HELP) patients: The Multicenter HELP Study. Am J Kidney Dis 2003; 41:1240-1246.
72. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM: Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800-809.
73. Mendelsohn ME, Karas RH: Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308:1583-1587.
74. Weisinger JR, Gonzalez L, Alvarez H, Hernandez E, Carlini RG, Capriles F, Cervino M, Martinis R, Paz-Martinez V, Bellorin-Font E: Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 2000; 58: 331-335.
75. Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR: Effects of ral-oxifene on bone metabolism and serum lip-ids in postmenopausal women on chronic hemodialysis. Kidney Int 2003; 63:2269-2274.
76. Kato S, Lindholm B, Axelsson J, Qureshi R A, Barany P, Heimburger O, Gustafsson JA, Stenvinkel P, Nordfors L: Association between oestrogen receptor alpha gene polymorphism and mortality in female end-stage renal disease patients. Nephrol Dial Transplant 2007; 22:2571-2577.
77. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C: Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 2005; 15:345-355.
78. Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M: Effect of megestrol acetate on serum albumin level in malnourished dialysis patients. J Ren Nutr 2009; 19: 167-171.
79. Guest S: Hypothesis: gender and encapsulating peritoneal sclerosis. Perit Dial Int 2009; 29: 489-491.
80. Guest S: Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009; 29:252-255.
81. Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, Barany P, Heimburger O, Stenvinkel P: Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2010, in press.
82. Palmer BF: Outcomes associated with hypo-gonadism in men with chronic kidney disease. Adv Chron Kidney Dis 2004; 11:342-347.
83. Dunkel L, Raivio T, Laine J, Holmberg C: Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997; 51: 777-784.
84. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Barany P, Heimburger O, Sten-vinkel P: Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20:613-620.
85. Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ: Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006; 47:251-262.
86. Traish AM, Saad F, Feeley RJ, Guay A: The dark side of testosterone deficiency. III. Cardiovascular disease. J Androl 2009; 30:477-494.
87. Johansen KL: Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chron Kidney Dis 2009; 16:501-510.
88. Gungor O, Kircelli F, Juan Jesus C, Asci G, Toz H, Tatar E, Hur E, Sever MS, Arinsoy T, Ok E: Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin J Am Soc Nephrol 2010, in press.
89. Doumouchtsis KK, Kostakis AI, Dou-mouchtsis SK, Grapsa EI, Passalidou IA, Tziamalis MP, Poulakou MV, Vlachos IS, Perrea DN: The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of rankl. Hemodial Int 2008; 12: 100-107.
90. Karakitsos D, Patrianakos AP, De Groot E, Boletis J, Karabinis A, Kyriazis J, Samonis G, Parthenakis FI, Vardas PE, Daphnis E: An-drogen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 2006; 26: 536-543.
91. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006; 17: 2307-2314.
92. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275-1281.
93. Avesani CM, Carrero JJ, Axelsson J, Qureshi AR, Lindholm B, Stenvinkel P: Inflammation and wasting in chronic kidney disease: pa r tners in crime. Kidney Int Suppl 2006:S8-S13. (Pubitemid 44764120)
94. Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B: Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr Opin Lipidol 2009; 20:3-9.
95. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kuro-kawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK: Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003; 64:254-262.
96. Kaveh K, Kimmel PL: Compliance in he-modialysis patients: multidimensional measures in search of a gold standard. Am J Kidney Dis 2001; 37: 244-266.
97. Takaki J, Yano E: Possible gender differences in the relationships of self-efficacy and the internal locus of control with compliance in hemodialysis patients. Behav Med 2006; 32:5-11.
98. Yeh SJ, Huang C, Chou H, Wan TTH: Gender differences in stress and coping among elderly patients on hemodialysis. Sex Roles 2009; 60:44-56.
99. Lindqvist R, Carlsson M, Sjoden PO: Coping strategies and quality of life among patients on hemodialysis a nd continuous ambulatory peritoneal dialysis. Scand J Caring Sci 1998; 12:223-230. (Pubitemid 29006159)
100. Yeh SC, Chou HC: Coping strategies and stressors in patients with hemodialysis. Psychosom Med 2007; 69: 182-190.
101. Vazquez I, Valderrabano F, Fort J, Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajar-do D: Gender differences in health-related quality of life in hemodialysis patients. Nefrologia 2004;XXIV:167-178.
102. Lopes GB, Matos CM, Leite EB, Martins MT, Martins MS, Silva LF, Robinson BM, Port FK, James SA, Lopes AA: Depression as a potential explanation for gender differences in health-related quality of life among patients on maintenance hemodialysis. Nephron Clin Pract 2010; 115:c35-c40.
103. Soldin OP, Mattison DR: Sex differences in pharmacokinetics and pharmacodynam-ics. Clin Pharmacokinet 2009; 48:143-157.
104. Spalding EM, Chandna SM, Davenport A, Farrington K: Kt/V underestimates the he-modialysis dose in women and small men. Kidney Int 2008; 74:348-355.
105. Daugirdas JT, Depner TA, Greene T, Kuhl-mann MK, Levin NW, Chertow GM, Rocco MV: Surface-area-normalized Kt/V: a method of rescaling dialysis dose to body surface area-implications for different-size patients by gender. Semin Dial 2008; 21: 415-421.
106. Eknoyan G, Beck GJ, Cheung AK, Daugir-das JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Eng l J Med 20 02; 347: 2010-2019.
107. Depner T, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G: Dialysis dose and the effect of gender and body size on outcome in the hemo study. Kidney Int 2004; 65: 1386-1394.
108. Port FK, Wolfe RA, Hulbert-Shearon TE, McCullough KP, Ashby VB, Held PJ: High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 2004; 43:1014-1023.
109. Daugirdas JT, Greene T, Chertow GM, Depner TA: Can rescaling dose of dialysis to body surface area in the hemo study explain the different responses to dose in women versus men? Clin J Am Soc Nephrol 2010, in press.
110. Couchoud C, Kooman J, Finne P, Leivestad T, Stojceva-Taneva O, Ponikvar JB, Collart F, Kramar R, de Francisco A, Jager KJ: From registry data collection to international comparisons: examples of haemodialysis duration and frequency. Nephrol Dial Transplant 2009; 24:217-224.
111. Miller CD, Robbin ML, Allon M: Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 20 03; 63: 346-352.
112. Wasse H, Hopson SD, McClellan W: Racial and gender differences in arteriovenous fistula use among incident hemodialysis patients. Am J Nephrol 2010; 32: 234-241.
113. Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK: Creation, cannulation and survival of arteriovenous fistulae: data from the dialysis outcomes and practice patterns study. Kidney Int 2003; 63:323-330.
114. Vernaglione L, Mele G, Cristofano C, Di-stratis C, Perrone F, Frascina M, Pennac-chiotti F, Chimienti S: Comorbid conditions and gender impact the primary survival of distal radio-cephalic arteriove-nous fistula inpatients on long-term hemo-dialysis. J Nephrol 2005; 18: 276-281.
115. Puskar D, Pasini J, Savic I, Bedalov G, Sonicki Z: Survival of primary arteriove-nous fistula in 463 patients on chronic he-modialysis. Croat Med J 2002; 43: 306-311.
116. Erkut B, Unlu Y, Ceviz M, Becit N, Ates A, Colak A, Kocak H: Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency. Ren Fail 2006; 28:275-281.
117. Caplin N, Sedlacek M, Teodorescu V, Falk A, Uribarri J: Venous access: women are equal. Am J Kidney Dis 2003; 41: 429-432.
118. Saran R, Elder SJ, Goodkin DA, Akiba T, Ethier J, Rayner HC, Saito A, Young EW, Gillespie BW, Merion RM, Pisoni RL: Enhanced training in vascular access creation predicts arteriovenous fistula placement and patency in hemodialysis patients: results from the dialysis outcomes and practice patterns study. Ann Surg 2008; 247: 885-891.
119. Shenoy S: Surgical anatomy of upper arm: what is needed for AVF planning. J Vasc Access 2009; 10: 223-232.
120. Rushton DH, Barth JH: What is the evidence for gender differences in ferritin and haemoglobin? Crit Rev Oncol Hematol 2010; 73: 1-9.
121. Di Iorio BR, Stellato D, De Santo NG, Ciril-lo M: Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 2004; 22: 423-427.